TD Cowen lowered the firm’s price target on PacBio to $15 from $19 and keeps an Outperform rating on the shares. The firm said the good news is $240M guidance is what most expected, it provides some cushion, and diligence continues to support a strong Revio cycle.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
- PACB Earnings this Week: How Will it Perform?
- Canaccord still bullish on 10x Genomics, PacBio despite reducing 2024 estimates
- Cathie Wood’s ARK Investment bought 908K shares of PacBio today
- Pac Bio call volume above normal and directionally bullish
